TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Soft Bifocal Contact Lens Myopia Control
Brief Summary: This study will evaluate the use of two different bifocal contact lens add powers to prevent further nearsighted progression in children ages 7 to 11 years old. It is theorized that the profile of the bifocal lenses will decrease the amount of change in nearsightedness that the children experience.


Options:
A: Arm Label: PAL; Type: EXPERIMENTAL; Interventions: Device: progressive addition spectacle lens (bifocal) | Arm Label: SVL; Type: ACTIVE_COMPARATOR; Interventions: Device: Single Vision Lenses (SVLs) | Intervention Type: DEVICE; Name: progressive addition spectacle lens (bifocal); Assigned to Arm(s): PAL | Intervention Type: DEVICE; Name: Single Vision Lenses (SVLs); Assigned to Arm(s): SVL
B: Arm Label: Biofinity; Type: ACTIVE_COMPARATOR; Interventions: Device: Biofinity | Arm Label: Biofinity Multifocal D +1.50 add; Type: EXPERIMENTAL; Interventions: Device: Biofinity Multifocal D +1.50 add | Arm Label: Biofinity Multifocal D +2.50 add; Type: EXPERIMENTAL; Interventions: Device: Biofinity Multifocal D +2.50 add | Intervention Type: DEVICE; Name: Biofinity Multifocal D +1.50 add; Assigned to Arm(s): Biofinity Multifocal D +1.50 add | Intervention Type: DEVICE; Name: Biofinity Multifocal D +2.50 add; Assigned to Arm(s): Biofinity Multifocal D +2.50 add | Intervention Type: DEVICE; Name: Biofinity; Assigned to Arm(s): Biofinity
C: Intervention Type: DRUG; Name: 0.25 % atropine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 0.5 % atropine; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: 0.25 % atropine+auricular acupoints; Assigned to Arm(s): N/A
D: Arm Label: Progressive addition lenses (PALs); Type: ACTIVE_COMPARATOR; Interventions: Device: Progressive Addition Lenses (PALs) | Arm Label: Single vision lenses (SVLs); Type: ACTIVE_COMPARATOR; Interventions: Device: Single Vision Lenses (SVLs) | Intervention Type: DEVICE; Name: Progressive Addition Lenses (PALs); Assigned to Arm(s): Progressive addition lenses (PALs) | Intervention Type: DEVICE; Name: Single Vision Lenses (SVLs); Assigned to Arm(s): Single vision lenses (SVLs)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Soft Bifocal Contact Lens Myopia Control
Brief Summary: This study will evaluate the use of two different bifocal contact lens add powers to prevent further nearsighted progression in children ages 7 to 11 years old. It is theorized that the profile of the bifocal lenses will decrease the amount of change in nearsightedness that the children experience.


Options:
A: Arm Label: Biofinity; Type: ACTIVE_COMPARATOR; Interventions: Device: Biofinity | Arm Label: Biofinity Multifocal D +1.50 add; Type: EXPERIMENTAL; Interventions: Device: Biofinity Multifocal D +1.50 add | Arm Label: Biofinity Multifocal D +2.50 add; Type: EXPERIMENTAL; Interventions: Device: Biofinity Multifocal D +2.50 add | Intervention Type: DEVICE; Name: Biofinity Multifocal D +1.50 add; Assigned to Arm(s): Biofinity Multifocal D +1.50 add | Intervention Type: DEVICE; Name: Biofinity Multifocal D +2.50 add; Assigned to Arm(s): Biofinity Multifocal D +2.50 add | Intervention Type: DEVICE; Name: Biofinity; Assigned to Arm(s): Biofinity
B: N/A
C: Arm Label: PAL; Type: EXPERIMENTAL; Interventions: Device: progressive addition spectacle lens (bifocal) | Arm Label: SVL; Type: ACTIVE_COMPARATOR; Interventions: Device: Single Vision Lenses (SVLs) | Intervention Type: DEVICE; Name: progressive addition spectacle lens (bifocal); Assigned to Arm(s): PAL | Intervention Type: DEVICE; Name: Single Vision Lenses (SVLs); Assigned to Arm(s): SVL
D: Intervention Type: DEVICE; Name: Polymethyl Methacrylate-Silicone Contact Lenses; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Polymethyl Methacrylate Contact Lenses; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Long-term Follow-up Study for Multiple Sclerosis Patients Who Have Completed the Alemtuzumab Extension Study (CAMMS03409)
Brief Summary: Primary Objective:

To evaluate long-term safety of alemtuzumab.

Secondary Objectives:

* To evaluate long term efficacy of alemtuzumab.
* To evaluate the safety profile of participants who received other Disease Modifying Treatment (DMT) following alemtuzumab treatment.
* To evaluate participant-reported Quality of Life (QoL) outcomes and health resource utilization of participant who received alemtuzumab.
* To evaluate as needed re-treatment with alemtuzumab and other DMTs.


Options:
A: Arm Label: Natalizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Natalizumab | Arm Label: Interferon-beta-1b; Type: EXPERIMENTAL; Interventions: Drug: interferon beta-1b | Intervention Type: DRUG; Name: interferon beta-1b; Assigned to Arm(s): Interferon-beta-1b | Intervention Type: DRUG; Name: Natalizumab; Assigned to Arm(s): Natalizumab
B: Arm Label: OMB 20 mg; Type: EXPERIMENTAL; Interventions: Drug: Ofatumumab subcutaneous injection, Drug: Teriflunomide-matching placebo capsules | Arm Label: TER 14 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Teriflunomide capsule, Drug: Matching placebo of ofatumumab subcutaneous injections | Intervention Type: DRUG; Name: Ofatumumab subcutaneous injection; Assigned to Arm(s): OMB 20 mg | Intervention Type: DRUG; Name: Teriflunomide-matching placebo capsules; Assigned to Arm(s): OMB 20 mg | Intervention Type: DRUG; Name: Teriflunomide capsule; Assigned to Arm(s): TER 14 mg | Intervention Type: DRUG; Name: Matching placebo of ofatumumab subcutaneous injections; Assigned to Arm(s): TER 14 mg
C: Arm Label: Alemtuzumab; Type: EXPERIMENTAL; Interventions: Drug: alemtuzumab GZ402673 | Intervention Type: DRUG; Name: alemtuzumab GZ402673; Assigned to Arm(s): Alemtuzumab
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Glatiramer acetate, Drug: Albuterol | Intervention Type: DRUG; Name: Glatiramer acetate; Assigned to Arm(s): 1, 2 | Intervention Type: DRUG; Name: Albuterol; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Albuterol placebo; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel or Vinflunine in Subjects With Recurrent or Progressive Metastatic Urothelial Cancer
Brief Summary: Participants with metastatic or locally advanced/unresectable urothelial cancer that has recurred or progressed following platinum-based chemotherapy will be randomly assigned to receive Investigator's choice of paclitaxel, docetaxel, or vinflunine (Control), or pembrolizumab. The primary study hypotheses are that pembrolizumab will prolong Overall Survival (OS) and Progression-free Survival (PFS) compared to paclitaxel, docetaxel, or vinflunine.


Options:
A: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Drug: paclitaxel, Drug: vinflunine, Drug: docetaxel | Arm Label: Pembrolizumab; Type: EXPERIMENTAL; Interventions: Biological: pembrolizumab | Intervention Type: BIOLOGICAL; Name: pembrolizumab; Assigned to Arm(s): Pembrolizumab | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: vinflunine; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: docetaxel; Assigned to Arm(s): Control
B: Arm Label: Cohort A: Triple Negative Breast Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort B: Head & Neck Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort C: Urothelial Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort D: Gastric Cancer; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: Cohort B2: Head & Neck Cancer Expansion; Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Cohort A: Triple Negative Breast Cancer, Cohort B2: Head & Neck Cancer Expansion, Cohort B: Head & Neck Cancer, Cohort C: Urothelial Cancer, Cohort D: Gastric Cancer
C: Arm Label: Atezolizumab; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Atezolizumab
D: Arm Label: Cohort 2: Participants With Second-line or Beyond Treatments; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Cohort 2: Participants With Second-line or Beyond Treatments

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The ability to control our blood glucose (sugar) concentrations after a meal is a strong predictor of the risk of disease. Our bodies respond to glucose ingestion by reducing the amount of glucose from the liver entering the bloodstream. At the same time muscle increases the amount of glucose it take up from the bloodstream. This ensures that our blood glucose levels do not get too high. The investigators want to understand what happens to these processes following exercise after breakfast and after an overnight fast. In addition, the investigators also want to understand whether exercising with or without breakfast influences our appetite, food intake and activity levels later in the day.


Options:
A: Arm Label: Breakfast Rest; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Breakfast | Arm Label: Breakfast Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise, Dietary Supplement: Breakfast | Arm Label: Fasted Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Breakfast Exercise, Fasted Exercise | Intervention Type: DIETARY_SUPPLEMENT; Name: Breakfast; Assigned to Arm(s): Breakfast Exercise, Breakfast Rest
B: Arm Label: Omitted Breakfast; Type: EXPERIMENTAL; Interventions: Other: Omitted Breakfast, Other: Breakfast | Arm Label: Breakfast; Type: ACTIVE_COMPARATOR; Interventions: Other: Omitted Breakfast, Other: Breakfast | Intervention Type: OTHER; Name: Omitted Breakfast; Assigned to Arm(s): Breakfast, Omitted Breakfast | Intervention Type: OTHER; Name: Breakfast; Assigned to Arm(s): Breakfast, Omitted Breakfast
C: Arm Label: Early Time-Restricted Feeding; Type: EXPERIMENTAL; Interventions: Behavioral: Early Time-Restricted Feeding, Behavioral: Structured Weight Loss Program | Arm Label: Control Schedule; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control Schedule, Behavioral: Structured Weight Loss Program | Intervention Type: BEHAVIORAL; Name: Early Time-Restricted Feeding; Assigned to Arm(s): Early Time-Restricted Feeding | Intervention Type: BEHAVIORAL; Name: Control Schedule; Assigned to Arm(s): Control Schedule | Intervention Type: BEHAVIORAL; Name: Structured Weight Loss Program; Assigned to Arm(s): Control Schedule, Early Time-Restricted Feeding
D: Arm Label: Intermittent Fasting; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Meal Replacement | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Meal Replacement; Assigned to Arm(s): Intermittent Fasting

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicentre, Double-blind, Randomized, Parallel Group, Phase 3 Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-acting β2 Agonist (BORA)
Brief Summary: The purpose of this study is to characterize the safety profile of benralizumab administration in asthma patients who have completed one of the three predecessor studies: D3250C00017, D3250C00018 or D3250C00020.


Options:
A: Arm Label: Benralizumab Arm A; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Arm Label: Benralizumab Arm B; Type: EXPERIMENTAL; Interventions: Biological: Benralizumab | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab Arm A | Intervention Type: BIOLOGICAL; Name: Benralizumab; Assigned to Arm(s): Benralizumab Arm B
B: Arm Label: Non-drug interventional group; Type: OTHER; Interventions: Drug: Short Acting Beta Agonist (SABA) | Intervention Type: DRUG; Name: Short Acting Beta Agonist (SABA); Assigned to Arm(s): Non-drug interventional group
C: Arm Label: 1; Type: OTHER; Interventions: Biological: IMA-638 is a biologic | Intervention Type: BIOLOGICAL; Name: IMA-638 is a biologic; Assigned to Arm(s): 1
D: Intervention Type: DRUG; Name: omalizumab; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-Term Integrated Telerehabilitation of COPD Patients. A Multi-Center Randomized Controlled Trial
Brief Summary: This research project aims to conduct a three-arm multi-center randomized controlled trial (RCT) on an innovative telerehabilitation intervention for patients with chronic obstructive pulmonary disease (COPD). The overall purpose of the RCT is to demonstrate whether long-term integrated telerehabilitation involving exercise training at home, telemonitoring, and education/self-management will prevent hospital readmissions, thus reducing healthcare costs, for patients with COPD, and will improve patient status and quality of life.


Options:
A: Arm Label: Usual Care; Type: OTHER; Interventions: Other: Usual Care | Arm Label: Internet-mediated Walking Program; Type: OTHER; Interventions: Behavioral: automated internet-mediated walking program | Intervention Type: BEHAVIORAL; Name: automated internet-mediated walking program; Assigned to Arm(s): Internet-mediated Walking Program | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
B: Arm Label: tiotropium + olodaterol; Type: EXPERIMENTAL; Interventions: Drug: tiotropium, Drug: olodaterol | Arm Label: tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: tiotropium | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium + olodaterol | Intervention Type: DRUG; Name: olodaterol; Assigned to Arm(s): tiotropium + olodaterol | Intervention Type: DRUG; Name: tiotropium; Assigned to Arm(s): tiotropium
C: Arm Label: resistance training; Type: EXPERIMENTAL; Interventions: Other: Resistance training | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Resistance training; Assigned to Arm(s): resistance training
D: Arm Label: Telerehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training at home, Behavioral: Telemonitoring and education/self-management | Arm Label: Unsupervised exercise training at home; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training at home | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise training at home; Assigned to Arm(s): Telerehabilitation, Unsupervised exercise training at home | Intervention Type: BEHAVIORAL; Name: Telemonitoring and education/self-management; Assigned to Arm(s): Telerehabilitation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-Term Integrated Telerehabilitation of COPD Patients. A Multi-Center Randomized Controlled Trial
Brief Summary: This research project aims to conduct a three-arm multi-center randomized controlled trial (RCT) on an innovative telerehabilitation intervention for patients with chronic obstructive pulmonary disease (COPD). The overall purpose of the RCT is to demonstrate whether long-term integrated telerehabilitation involving exercise training at home, telemonitoring, and education/self-management will prevent hospital readmissions, thus reducing healthcare costs, for patients with COPD, and will improve patient status and quality of life.


Options:
A: Arm Label: Telerehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training at home, Behavioral: Telemonitoring and education/self-management | Arm Label: Unsupervised exercise training at home; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training at home | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise training at home; Assigned to Arm(s): Telerehabilitation, Unsupervised exercise training at home | Intervention Type: BEHAVIORAL; Name: Telemonitoring and education/self-management; Assigned to Arm(s): Telerehabilitation
B: Arm Label: ACCESS; Type: EXPERIMENTAL; Interventions: Behavioral: ACCESS | Arm Label: Enhanced Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: ACCESS; Assigned to Arm(s): ACCESS
C: Arm Label: Psychoeducative intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Psychoeducative intervention | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Psychoeducative intervention; Assigned to Arm(s): Psychoeducative intervention
D: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Coaching program; Type: EXPERIMENTAL; Interventions: Other: Coaching program | Intervention Type: OTHER; Name: Coaching program; Assigned to Arm(s): Coaching program

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-Term Integrated Telerehabilitation of COPD Patients. A Multi-Center Randomized Controlled Trial
Brief Summary: This research project aims to conduct a three-arm multi-center randomized controlled trial (RCT) on an innovative telerehabilitation intervention for patients with chronic obstructive pulmonary disease (COPD). The overall purpose of the RCT is to demonstrate whether long-term integrated telerehabilitation involving exercise training at home, telemonitoring, and education/self-management will prevent hospital readmissions, thus reducing healthcare costs, for patients with COPD, and will improve patient status and quality of life.


Options:
A: Arm Label: Control group (Group A); Type: ACTIVE_COMPARATOR; Interventions: Other: Usual care | Arm Label: Intervention group (Group B); Type: OTHER; Interventions: Other: Home-based telehealth program, Other: Home-based rehabilitation, Other: Usual care | Intervention Type: OTHER; Name: Home-based telehealth program; Assigned to Arm(s): Intervention group (Group B) | Intervention Type: OTHER; Name: Home-based rehabilitation; Assigned to Arm(s): Intervention group (Group B) | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Control group (Group A), Intervention group (Group B)
B: Arm Label: Device: KAIA COPD-App (Medical Mobile Application).; Type: EXPERIMENTAL; Interventions: Device: Kaia COPD Application | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care | Intervention Type: DEVICE; Name: Kaia COPD Application; Assigned to Arm(s): Device: KAIA COPD-App (Medical Mobile Application). | Intervention Type: OTHER; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: Pulmonary Telerehabilitation Intervention Group; Type: EXPERIMENTAL; Interventions: Behavioral: Pulmonary Telerehabilitation | Arm Label: Usual Care Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pulmonary Telerehabilitation; Assigned to Arm(s): Pulmonary Telerehabilitation Intervention Group
D: Arm Label: Telerehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training at home, Behavioral: Telemonitoring and education/self-management | Arm Label: Unsupervised exercise training at home; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training at home | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise training at home; Assigned to Arm(s): Telerehabilitation, Unsupervised exercise training at home | Intervention Type: BEHAVIORAL; Name: Telemonitoring and education/self-management; Assigned to Arm(s): Telerehabilitation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-Term Integrated Telerehabilitation of COPD Patients. A Multi-Center Randomized Controlled Trial
Brief Summary: This research project aims to conduct a three-arm multi-center randomized controlled trial (RCT) on an innovative telerehabilitation intervention for patients with chronic obstructive pulmonary disease (COPD). The overall purpose of the RCT is to demonstrate whether long-term integrated telerehabilitation involving exercise training at home, telemonitoring, and education/self-management will prevent hospital readmissions, thus reducing healthcare costs, for patients with COPD, and will improve patient status and quality of life.


Options:
A: Arm Label: Telerehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training at home, Behavioral: Telemonitoring and education/self-management | Arm Label: Unsupervised exercise training at home; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise training at home | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise training at home; Assigned to Arm(s): Telerehabilitation, Unsupervised exercise training at home | Intervention Type: BEHAVIORAL; Name: Telemonitoring and education/self-management; Assigned to Arm(s): Telerehabilitation
B: Arm Label: COPD, Telehealth; Type: EXPERIMENTAL; Interventions: Device: Telehealth | Arm Label: COPD, Normal clinical practice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Telehealth; Assigned to Arm(s): COPD, Telehealth
C: Arm Label: COPD education + Usual care; Type: ACTIVE_COMPARATOR; Interventions: Other: COPD education + Usual care | Arm Label: Physical activity self-management; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity self-management | Intervention Type: BEHAVIORAL; Name: Physical activity self-management; Assigned to Arm(s): Physical activity self-management | Intervention Type: OTHER; Name: COPD education + Usual care; Assigned to Arm(s): COPD education + Usual care
D: Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Other: Telehealth Pulmonary Rehabilitation | Intervention Type: OTHER; Name: Telehealth Pulmonary Rehabilitation; Assigned to Arm(s): Intervention

Answer: A